Chronic Myelogenous Leukemia (CML) management has been revolutionized by Tyrosine Kinase Inhibitors (TKIs), turning a once-fatal disease into a manageable chronic condition. At the heart of this success story lies precise and reliable monitoring of the BCR-ABL fusion gene—the definitive molecular driver of CML.
Beyond initial diagnosis, BCR-ABL quantification is the cornerstone of effective, lifelong patient management. It provides clinicians with the critical data needed to:
Establish a Baseline at diagnosis.
Evaluate Early Treatment Response and predict long-term outcomes.
Guide TKI Therapy Adjustments based on molecular response milestones.
Monitor for Minimal Residual Disease (MRD) and potential relapse.
However, Unreliable detection can compromise these decisions.
Macro & Micro-Test’s Human BCR-ABL Fusion Gene Mutation Detection Kit is engineered to deliver the precision required for confidence at every stage.
Why Our Solution is a Trusted Partner in CML Care:
- Comprehensive Profiling: Simultaneously detects three major BCR-ABL transcripts (P210, P190, P230), ensuring no critical case is missed.
- Unmatched Sensitivity: Achieves a limit of detection (LoD) as low as 1,000 copies/mL, enabling early and accurate assessment of deep molecular responses.
- Rigorous Accuracy: Incorporates an internal control and UNG enzyme system to eliminate false positives/negatives, safeguarding result integrity.
- Streamlined Workflow: Features a closed-tube, post-PCR-free operation, delivering objective results in under 60 minutes to accelerate clinical decision-making.
- Operational Flexibility: Offered in liquid andlyophilized formats to suit diverse laboratory preference.
Embrace the gold standard in molecular monitoring. Empower your clinic with the precision needed to optimize lifelong care for your CML patients.Contact for more details: marketing@mmtest.com
Post time: Sep-29-2025